Correlation between a single nucleotide polymorphism (G/T at nt –88) in the Mx1 gene promoter and the response to interferon therapy for hepatitis C virus in Egyptian patients
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | S. Mohamed, Mervat | |
| dc.contributor.author | F. Sabet, Salwa | |
| dc.contributor.author | M. Moustafa, Mohamed | |
| dc.contributor.author | S. Salama, Mohamed | |
| dc.date.accessioned | 2020-02-08T11:29:06Z | |
| dc.date.available | 2020-02-08T11:29:06Z | |
| dc.date.issued | 2011 | |
| dc.description | MSA Google Scholar | en_US |
| dc.description.abstract | Interferon used in the treatment of hepatitis C virus (HCV) patients stimulates the expression of a number of host genes encoding enzymes with antiviral activities, including myxovirus resistance gene1 (Mx1). Mx1 gene was found to have a single nucleotide polymorphism (SNP) at position -88 in the promotor region that affect the expression of Mx 1 protein and was suggested to be associated with the response of HCV. In this study, we assessed the relation between the SNP in the Mx1 gene and the responsiveness of Egyptian HCV patients to pegylated interferon and ribavirin treatment along with other host-related and virus-related predictors of treatment outcome. We genotyped the biallelic G/T SNP in the promoter region of Mx1 gene at position -88 from the transcription start site by restriction fragment length polymorphism (RFLP) in 42 interferon treatment-naïve Egyptian patients that were treated with pegylated interferon and ribavirin. We found that Mx1 nt-88 SNP is not significantly correlated to achieving sustained virological response (SVR) after pegylated interferon alpha and ribavirin combined treatment. We conclude that Mx1 gene polymorphism at codon nt-88 cannot be considered as biological marker to potentially identify responders and non-responders of HCV patients to achieve a sustained virological response to treatment with interferon (IFN) in combination with ribavirin. | en_US |
| dc.identifier.citation | Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S (2005). Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 43: 623-629. Chieux V, Hober D, Harvey J, Lion G, Lucidarme D, Forzy G, Duhamel M, Cousin J, Ducoulombier H, Wattré P (1998). The Mx1 protein levels in whole blood lysates of patients with various viral infections. J. Virol . Methods, 70: 183-191. ElHefnawi MM, Zada S, El-Azab IA (2010). Prediction of prognostic biomarkers for Interferon-based therapy to Hepatitis C Virus patients: a metaanalysis of the NS5A protein in subtypes 1a, 1b, and 3a. Virol. J. 7: 130-137. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group (2008). Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterol, 135: 451-458. Fernández M, Quiroga JA, Martín J, Herrero M, Pardo M, Horisberger MA, Carreño V (1999). In vivo and in vitro induction of Mx1 protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J. Infect. Dis. 180: 262-267. Hijikata M, Ohta Y, Mishiro S (2000). Identification of a single nucleotide polymorphism in the Mx1 gene promoter (G/T at nt _88) correlated with the response of hepatitis C patients to interferon1. Intervirol. 43: 124-127. Jain MK, Zoellner C (2010). Role of ribavirin in HCV treatment response: now and in the future. Expert Opin. Pharmacother. 11: 673-683. Jamall IS, Yusuf S, Azhar M, Jamall S (2008). Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?. World J. Gastroenterol. 14: 6627-6631. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV, Thursz MR (2003). Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of Mx1 , OAS-1 and PKR. Genes Immunity, 4: 411-9. Malta Fde M, Medeiros-Filho JE, Azevedo RS, Gonçalves L, Silva LC, Carrilho FJ, Pinho JR (2010). Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.Mem. Inst. Oswaldo. Cruz. 105: 92-98. Pearlman BL, Sjogren MH (2010). Treatment Options for HCV Nonresponders and Relapse Patients. Gastroenterol . Hepatol. 6: 1- 12. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000). Is an ‘‘a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology, 31: 211-218. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ (2009). Hadziyannis, Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J. Viral. Hepat. 16: 724- 731. Samuel CE (2001). Antiviral actions of interferons. Clin. Microbiol. Rev.14: 778-809. Shaker O, Ahmed A, Doss W, Abdel-Hamid M (2009). Mx1 expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J. Viral. Hepatitis, 17: 794-799. Simmonds P, Bukh J, Combet C., Deleage G, EnomotoN, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatol. 42: 962-973. Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X, Howell C, Ramcharran D, Rosen HR, Taylor MW, Liang TJ, Yang H (2008). Virahep-C Study Group. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon stimulated genes with the response to interferon therapy for chronic hepatitis C. J. Hepatol. 49: 184-191. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Takagi K, Satoh J, Kumada H (2004). Single nucleotide polymorphism of the Mx1 gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepatitis. 11: 271-276. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL (2008). Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepat. 47: 1884- 1893. | en_US |
| dc.identifier.doi | https://doi.org/10.5897/AJB11.1522 | |
| dc.identifier.issn | 1684–5315 | |
| dc.identifier.other | https://doi.org/10.5897/AJB11.1522 | |
| dc.identifier.uri | https://t.ly/dNrqM | |
| dc.language.iso | en | en_US |
| dc.publisher | Academic Journals (Kenya) | en_US |
| dc.relation.ispartofseries | African Journal of Biotechnology;Vol. 10(62), pp. 13376-13382, | |
| dc.subject | Hepatitis C virus (HCV) | en_US |
| dc.subject | interferon (IFN) | en_US |
| dc.subject | myxovirus resistance protein (Mx1 protein) | en_US |
| dc.subject | myxovirus resistance gene-1 (Mx1 gene) | en_US |
| dc.subject | single nucleotide polymorphism (SNP). | en_US |
| dc.title | Correlation between a single nucleotide polymorphism (G/T at nt –88) in the Mx1 gene promoter and the response to interferon therapy for hepatitis C virus in Egyptian patients | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 51 B
- Format:
- Item-specific license agreed upon to submission
- Description: